Betamethasone vs Dextrose Injections in Trigger Finger
ConditionTrigger Finger
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorIstanbul University - Cerrahpasa
About this trial
This study aims to compare the effectiveness of ultrasound-guided betamethasone and dextrose injections in patients with trigger finger.
Trigger finger is a common hand condition characterized by pain, clicking, and locking of the finger due to tendon entrapment at the A1 pulley. Corticosteroid injections are widely used as a first-line treatment; however, they may be associated with potential side effects.
Dextrose injection is an alternative treatment that may promote tissue healing through regenerative mechanisms. However, there is limited high-quality evidence regarding its effectiveness in trigger finger.
In this randomized controlled trial, patients will be assigned to receive either betamethasone or dextrose injection under ultrasound guidance. The primary outcome will be pain intensity measured by the Numeric Rating Scale (NRS). Secondary outcomes will include triggering severity, hand function, grip and pinch strength, and fine motor skills evaluated over a 12-week follow-up period.
The results of this study may help determine whether dextrose injection is a safe and effective alternative to corticosteroid treatment in trigger finger.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age between 18 and 75 years
Clinical diagnosis of trigger finger
Presence of symptoms for at least 4 weeks
Disqualifiers
Previous surgery on the affected finger
Injection treatment to the affected finger within the previous 3 months
Active local or systemic infection
Active malignancy
Trial design
Design model
Parallel
Treatments tested in this trial
Betamethasone
DrugUltrasound-guided injection of 1 ml lidocaine combined with 1 ml betamethasone administered at the A1 pulley level for the treatment of trigger finger.
Dextrose Injection
Other interventionUltrasound-guided injection of 1 ml lidocaine combined with 1 ml 30% dextrose solution resulting in a final concentration of 15% dextrose, administered at the A1 pulley level for the treatment of trigger finger.
Treatment groups
42 Participants
are divided into 2 treatment groupsGroup A: Betamethasone InjectionActive comparator 1 intervention
Group B: Dextrose InjectionActive comparator 1 intervention
Trial outcomes
Primary outcomes
1
Change in pain intensity assessed by Numeric Rating Scale (NRS)
Pain intensity will be evaluated using the 11-point Numeric Rating Scale (NRS), where 0 indicates no pain and 10 indicates worst imaginable pain.
Time frame
Baseline, 1 hour, 2 weeks, 4 weeks, and 12 weeksSecondary outcomes
1
Change in triggering severity assessed by Modified Quinnell classification
Triggering severity will be evaluated using the Modified Quinnell classification system.
Time frame
Baseline, 2 weeks, 4 weeks, and 12 weeks2
Change in hand function assessed by QuickDASH
Functional status will be assessed using the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) questionnaire.
Time frame
Baseline, 2 weeks, 4 weeks, and 12 weeks3
Change in grip strength
Grip strength will be measured using a hand dynamometer.
Time frame
Baseline, 2 weeks, 4 weeks, and 12 weeks4
Change in pinch strength
Pinch strength will be measured using a pinch meter.
Time frame
Baseline, 2 weeks, 4 weeks, and 12 weeksSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov